Drugs online research references
Am J Pathol. 1992 Jun;140(6):1357-63.
Dose-related effects of doxazosin on plasma lipids and aortic fatty streak formation in the hypercholesterolemic hamster model.
Foxall TL, Shwaery GT, Stucchi AF, Nicolosi RJ, Wong SS.
Department of Animal and Nutritional Sciences, University of New Hampshire, Durham.
Doxazosin, an alpha 1-adrenergic inhibitor, has been shown to decrease hypertension and plasma lipids, especially total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C), thus reducing certain risk factors associated with increased incidence of cardiovascular disease. One preliminary report indicated that the decrease in LDL-C in hypercholesterolemic hamsters treated with doxazosin was associated with a reduction in fatty streak formation. However, since the effects of doxazosin on plasma lipids, aortic fatty streak development, or the relationship between the two have not been studied in a dose-dependent manner, these effects were further investigated over varying doses of doxazosin (0, 1, 5, 10, and 20 mg/kg body wt/day) during a 10-week period. Doxazosin administration was associated with a dose-dependent decrease in LDL-C of 2%, 29%, 52%, and 60%, whereas the degree of fatty streak formation was reduced 11%, 45%, 76%, and 92% compared with controls, with the first statistically significant decrease for both parameters at the 10 mg/kg dose. Significant correlations between LDL-C concentrations and fatty streak area suggest that doxazosin altered aortic lipid infiltration primarily by its effect on plasma lipids. However, the 20 mg/kg dose of doxazosin significantly decreased lesion area compared with the 10 mg/kg dose without a further effect on plasma lipid concentrations. Three animals at these higher doses demonstrated no stainable lipid inclusions while maintaining plasma lipid values similar to their cohorts. These exceptions to the lipid-lesion relationship raise the possibility of additional effects of doxazosin, which may occur independent of or in concert with lipoprotein cholesterol lowering, on lesion formation.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1351367&dopt=Abstract
J Hum Hypertens. 1992 Jun;6(3):181-4.
Combined effect of doxazosin and pindolol on blood pressure control and lipid concentrations in patients with essential hypertension selected from general practice. Hunter Hypertension Research Group.
[No authors listed]
Doxazosin, an alpha-adrenergic antagonist with potentially favourable effects on lipid status was evaluated in 25 otherwise healthy general practice patients with mild to moderate hypertension. A mean dose of 5.7 mg produced a significant fall in lying and standing systolic and diastolic blood pressure over an 11 week period as well as an 8% increase in HDL cholesterol and a 7.5% decrease in the total cholesterol/HDL cholesterol ratio. Following this, the doxazosin dose was halved and pindolol, a beta-blocker with intrinsic sympathomimetic activity, was added (mean dose 7.8 mg) to maintain blood pressure control. At the completion of 11 weeks of combined alpha- and beta-blockade, HDL cholesterol and triglyceride levels were found to be unaltered when compared to pretreatment; however there was a small but significant fall in total cholesterol. This study demonstrates that this combination of alpha- and beta-blocking antihypertensive therapy can produce potentially favourable blood lipid changes.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1352827&dopt=Abstract
Fortschr Med. 1992 Jun 20;110(17):330-2.
[Pharmacologic profile of urapidil. Consequences for use as an antihypertensive drug]
[Article in German]
van Zwieten PA.
Abteilungen Pharmakotherapie und Kardiologie, Medizinische Fakultat, Akademisch Medizinisches Zentrum, Amsterdam.
Urapidil, a phenylpiperazine-substituted derivative of uracil, is an example of an anti-hypertensive which lowers elevated blood pressure via at least two different mechanisms. As such, it belongs to the multifactorial or hybrid anti-hypertensives. Urapidil is a peripherally acting alpha 1-adrenoceptor antagonist, and, in this regard, is comparable with prazosin and its successor compounds (e.g. doxazosin). In addition, urapidil lowers elevated blood pressure via a central mechanism which is new and differs from that of the classical antihypertensives with a central nervous effect (clonidine, etc.). This additional mechanism favourably influences the side effect profile of urapidil.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1353745&dopt=Abstract
online pharmacies ||
Hair Million herbal formula for hair loss and hair growth ||
Amoxicillin ||
Tramadol ||
Paxil ||
Rx Drugs USA, Prescription Drugs Online Pharmacy ||
Zithromax ||
online pharmacy ||
Antibiotics and prescription medications online literature ||
Antibiotics